Multiplex Antigen Near-Patient Tests in Respiratory Tract Infections

By HEOR Staff Writer

November 7, 2023

Multiplex Antigen Near-Patient Tests

Understanding Respiratory Tract Infections (RTIs)

RTIs are some of the most common illnesses, causing a significant number of outbreaks annually. Viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) are often the culprits. These RTIs lead to a surge in hospital admissions during winter months, and their symptoms can be very similar, making it challenging to differentiate between them.

Multiplex Antigen Near-Patient Tests

Laboratories typically conduct the gold standard for these tests, reverse transcription polymerase chain reaction (RT-PCR). On the other hand, antigen near-patient tests (NPTs) offer quicker, more affordable, and easier testing. These tests can identify many viruses in multiplex tests or just one virus in singleplex tests, but they are less accurate overall. 

For the purpose of managing and identifying RTIs in primary and residential care settings, multiplex antigen NPTs may be helpful. Their viability and effectiveness are still unknown, though. Although the company states that these tests have acceptable diagnostic accuracy, there are questions regarding the sensitivity of these tests. This applies especially to RSV and influenza. This may reduce their usefulness in contexts involving primary or residential care.

The Current State of Affairs

There is limited guidance available on the use of multiplex antigen NPTs. Two international recommendations were identified, one from the Public Health Laboratory Network and Communicable Diseases Network Australia, which did not recommend the use of these tests. Another evaluation report by the Haute Autorité de Santé (HAS) in France found no clear medical benefit to using these tests in primary care settings. The World Health Organisation ACT-Accelerator Transition Plan has supported the development and acceleration of access to affordable COVID-19 rapid antigen diagnostic tests. This highlights potential interest in these and related technologies.

The Road Ahead

Given the uncertainties surrounding the effectiveness and feasibility of multiplex antigen NPTs in primary and residential care facilities, further studies are required. These studies should prospectively assess the diagnostic performance and clinical utility of multiplex antigen NPTs. The goal is to inform public policy on the use of these tests in these settings. Potentially helping to reduce inappropriate antibiotic use or emergency department visits for non-serious infections.

Reference url

Recent Posts

real-world evidence Portugal
Enhancing Health Technology Assessment Through Real-World Evidence in Portugal

By João L. Carapinha

June 17, 2026

Real-world evidence Portugal has moved from supplementary tool to statutory requirement under Decree-Law 118/2026, which compels national health systems to share interoperable data so that promised outcomes can be verified after medicines and devices reach patients. The legislation converts one-t...
Portuguese HTA Regulation
Integrating the Portuguese HTA Regulation into National Health Systems

By João L. Carapinha

June 17, 2026

The Portuguese HTA Regulation has delivered the most significant overhaul of the National System for Health Technology Assessment (SiNATS) since its creation in 2015. Published through Decreto-Lei n.º 118/2026, ...
AI PICO Scoping Tool
Pioneering AI PICO Scoping Tool Enhances EU Joint Clinical Assessments

By João L. Carapinha

June 17, 2026

A recently published AI PICO Scoping Tool delivers a practical solution for the demanding requirements of EU Joint Clinical Assessments by automatically extracting and consolidating Population, Intervention, Comparator, and Outcome (PICO) elements from disparate health technology assessment repor...